Top Page
Abbisko Cayman Limited
(2256)
Abbisko Cayman Limited (2256) vs. iShares MSCI Hong Kong ETF (EWH)
Abbisko Cayman Limited Business Overview & Revenue Model
Abbisko Cayman Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 503.99M | 19.06M | 0.00 | 22.68M | 0.00 | Gross Profit |
| 503.99M | 19.06M | 0.00 | 22.68M | 0.00 | EBIT |
| -21.59M | -511.08M | -492.92M | -1.81B | -706.47M | EBITDA |
| -15.28M | -410.99M | -492.62M | -1.80B | -696.98M | Net Income Common Stockholders |
| 28.30M | -431.58M | -498.29M | -1.81B | -706.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.96B | 2.01B | 2.35B | 2.55B | 617.77M | Total Assets |
| 2.11B | 2.12B | 2.49B | 2.65B | 665.97M | Total Debt |
| 24.29M | 35.72M | 45.58M | 53.80M | 4.31M | Net Debt |
| -265.25M | -1.94B | -2.21B | -2.49B | -613.47M | Total Liabilities |
| 148.71M | 134.28M | 143.16M | 118.48M | 1.77B | Stockholders Equity |
| 1.96B | 1.98B | 2.35B | 2.54B | -1.10B |
| Cash Flow | Free Cash Flow | |||
| -20.32M | -456.98M | -366.64M | -182.08M | -121.60M | Operating Cash Flow |
| -12.92M | -444.73M | -343.90M | -169.74M | -117.56M | Investing Cash Flow |
| -196.50M | 378.52M | -216.57M | -1.46B | -11.25M | Financing Cash Flow |
| -80.86M | -16.11M | -20.81M | 2.10B | 505.89M |
Abbisko Cayman Limited Technical Analysis
Abbisko Cayman Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$6.96B | 174.45 | 1.43% | ― | 2433.62% | ― | |
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% | |
| €4.19B | ― | -32.29% | ― | ― | ― | ||
| €476.99M | ― | -10.43% | ― | ― | ― | ||
62 Neutral | HK$3.78B | 21.21 | 4.47% | ― | -9.75% | ― | |
55 Neutral | HK$85.68B | ― | -8.98% | ― | -54.66% | -123.11% | |
49 Neutral | HK$2.46B | ― | -2.19% | ― | 5.32% | 89.43% |
Abbisko Cayman Limited Corporate Events
Abbisko Cayman Limited announced an increase in shareholding by its founder and CEO, Dr. Xu Yao-Chang, who purchased 17,000 ordinary shares, bringing his total shareholding to approximately 11.77% of the company. This move reflects Dr. Xu’s confidence in the company’s growth prospects. Additionally, the company has been executing a share repurchase plan, buying back 8,695,000 shares to date, which the board believes will enhance shareholder value as the current trading price undervalues the company’s intrinsic worth.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Cayman Limited announced that Mr. Sun Hongbin, an independent non-executive director of the company, has been publicly criticized by the Hong Kong Stock Exchange for his conduct during his tenure at New Century Healthcare. The criticism pertains to his failure to ensure adequate steps were taken to collect receivables and safeguard interests at New Century Healthcare. Despite this, Abbisko’s board has assessed the situation and believes it will not adversely impact the company’s operations or business.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received acceptance from the China National Medical Products Administration (NMPA) for the New Drug Application (NDA) of pimicotinib, a CSF-1R inhibitor, for treating Tenosynovial Giant Cell Tumor (TGCT). This marks a significant milestone as pimicotinib is the first internally discovered drug by Abbisko to enter the NDA process, showing promising clinical efficacy and safety. The drug has received Priority Review and Breakthrough Therapy Designation in China, and similar recognitions in the US and EU, indicating its potential impact on the market and stakeholders. Abbisko has partnered with Merck for the global commercialization of pimicotinib, which demonstrated significant improvements in clinical trials presented at the 2025 ASCO Annual Meeting.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Therapeutics has received an $85 million global commercialization option fee from Merck for pimicotinib (ABSK021), a CSF-1R inhibitor, under a licensing agreement. This fee will be recognized as revenue in 2025. The agreement allows Merck to commercialize pimicotinib worldwide, with Abbisko eligible for up to $605.5 million in milestone payments and royalties. Pimicotinib has shown promising results in treating tenosynovial giant cell tumor (TGCT) and has received multiple regulatory designations, highlighting its potential impact in the oncology market.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Therapeutics has announced that its small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received Breakthrough Therapy Designation from the China National Medical Products Administration for treating Hepatocellular Carcinoma (HCC). This designation is based on promising Phase I clinical trial data and aims to expedite the drug’s approval process, offering new hope for patients with advanced HCC, particularly those with FGF19 overexpression. The company is also conducting a pivotal registrational clinical study and exploring combination therapies to enhance treatment efficacy.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, will present the results of its phase 3 study on pimicotinib at the 2025 ASCO Annual Meeting. This presentation will cover the efficacy, safety, and clinical outcomes of pimicotinib in treating TGCT, potentially impacting Abbisko’s market positioning and stakeholder interests, especially given the drug’s breakthrough therapy designations.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Therapeutics announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been granted Priority Review status by the China National Medical Products Administration for treating Tenosynovial Giant Cell Tumor (TGCT). This designation is expected to expedite the review process, potentially allowing quicker access for patients. Pimicotinib has previously received Breakthrough Therapy Designation from both the China NMPA and the US FDA, and Priority Medicine designation from the European Medicines Agency. The drug has shown promising results in clinical trials, meeting all primary and secondary endpoints with a significant objective response rate.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Cayman Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Shanghai. Key agenda items include the approval of the company’s audited financial statements for 2024, re-election of directors, and authorization for the board to fix directors’ remuneration. Additionally, the company seeks approval to re-appoint Ernst & Young as auditors and to authorize the board to manage share allotments, potentially impacting the company’s capital structure and shareholder value.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, will present updated results from a Phase 2 study of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma at the 2025 ESMO GI Congress. The study highlights the combination’s favorable safety and promising anti-tumor activity, particularly in FGF19+ HCC patients, indicating potential advancements in treatment options for this cancer type.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
Abbisko Cayman Limited announced an increase in shareholding by its founder and CEO, Dr. Xu Yao-Chang, who purchased 30,000 shares, reflecting his confidence in the company’s growth prospects. Additionally, the company has repurchased 4,798,000 shares under its Share Repurchase Plan, indicating that the current trading price undervalues its business potential.
Abbisko Therapeutics announced the presentation of four late-breaking pre-clinical research results at the 2025 American Association for Cancer Research conference. The studies focused on ABSK112, ABSK131, and ABK-KRAS-1 inhibitors, highlighting their potential in treating cancer and addressing resistance mechanisms. These findings could significantly impact Abbisko’s market positioning by advancing their therapeutic pipeline and offering new treatment strategies for cancer patients.
Abbisko Cayman Limited announced amendments to its Post-IPO RSU and Share Option Schemes, allowing the use of treasury shares to satisfy grants and exercises. This aligns with recent changes in the Listing Rules, providing the company with greater flexibility in managing these schemes and potentially enhancing its operational efficiency.
Abbisko Therapeutics announced that Merck has exercised its global commercialization option for pimicotinib, a CSF-1R inhibitor, under their licensing agreement. This move, involving an option exercise fee of USD85 million, signifies a deepening collaboration and confidence in pimicotinib’s potential, especially after its successful Phase III trial results for treating tenosynovial giant cell tumor. The agreement could lead to Abbisko receiving up to USD605.5 million in payments, highlighting a significant impact on the company’s financial and industry positioning.
Abbisko Therapeutics announced that the Center for Drug Evaluation of the China National Medical Products Administration has cleared the IND application for ABSK061, a highly selective FGFR2/3 inhibitor, for treating children with achondroplasia. This development marks a significant step for Abbisko as ABSK061 is the first FGFR2/3 inhibitor to enter clinical trials globally, aiming to provide a wider therapeutic window and improved clinical efficacy compared to first-generation inhibitors, potentially impacting the treatment landscape for achondroplasia, a rare disorder with no specific treatments in China.
Abbisko Cayman Limited announced a cooperation agreement between its subsidiary, Abbisko Therapeutics, and Shanghai Allist Pharmaceuticals to explore the combination of Abbisko’s ABSK043 and Allist’s glecirasib for treating non-small cell lung cancer (NSCLC) patients with KRAS-G12C mutation. This collaboration aims to leverage the promising results of ABSK043, which has shown favorable safety and anti-tumor activity in early trials, potentially enhancing Abbisko’s position in the oncology market and offering new hope for NSCLC treatment.